Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, has announced the launch of new drug management modules for its interactive response technology (IRT) system. The advancements are designed to enhance efficiency and drug accountability, while also boosting quality assurance and patient safety in clinical trials.
“Cenduit’s latest enhancements help streamline drug supply chain management so patients get their study medications at every visit and no site or depot has a stock-out issue,” said Kim Lanza-Russo, director of product management, Cenduit. “Providing the guidance sponsors need to build an advanced and automated IRT system, Cenduit’s platform offers the functionalities needed to utilize drug supply chain management as a strategic asset in the success of a clinical trial study.”
From drug relabeling to materials management, Cenduit’s newest web-based enhancements give clinical trial managers more insight and control over their IRT system—providing them with the ability to view and make adjustments in real-time to ensure a seamless study all around.
With Cenduit as an IRT partner, sponsors can rest easy knowing their entire clinical supply chain is optimized – from packaging and release through returns and destruction. Cenduit’s intelligent systems provide automated support for even the most complex depot and site resupply algorithms and easily handle vital factors such as expiry date management, on-demand supply needs, temperature excursion management and similar demands.